The Effect of Berberine Supplementation on Glycemic Control and Inflammatory Biomarkers in Metabolic Disorders: An Umbrella Meta-analysis of Randomized Controlled Trials

• Published in: Clinical therapeutics 2024-02, Vol.46 (2), p.e64-e72
• Main Authors: Nazari, Ahmad, Ghotbabadi, Zahra Rostami, Kazemi, Kimia Sadat, Metghalchi, Yalda, Tavakoli, Reza, Rahimabadi, Razieh Ziaei, Ghaheri, Mohammad
• Format: Article
• Language: English
• Subjects: Adult; BBR; Berberine; Berberine - pharmacology; Berberine - therapeutic use; Biomarkers; Blood Glucose; C-reactive protein; Diabetes; Diabetes Mellitus, Type 2; Dietary Supplements; Disease; Drug dosages; Glucose; Glycemic; Glycemic Control; Hemoglobin; Homeostasis; Humans; Inflammation; Insulin; Insulin Resistance; Intervention; Maximum likelihood method; Meta-analysis; Meta-Analysis as Topic; Metabolic Diseases; Metabolic disorders; Metabolism; Obesity; Polycystic ovary syndrome; Randomized Controlled Trials as Topic; Statistical analysis; Supplements; Tumor necrosis factor-TNF; Tumor necrosis factor-α; Type 2 diabetes; Umbrella meta-analysis
• ISSN: 0149-2918; 1879-114X
• DOI: 10.1016/j.clinthera.2023.10.019

Several meta-analyses reported berberine (BBR) supplementation improves glycemic parameters and inflammatory marker, but findings remain inconsistent. Therefore, this study was conducted. We systematically searched PubMed, Embase, Web of Science, Scopus, and Google Scholar to identify the relevant meta-analyses up to April 2023. BBR supplementation was effective in reducing fasting blood glucose (FBG) (ESWMD: −0.77; 95% CI: −0.90 to −0.63, and ESSMD: −0.65; 95% CI: −0.83 to −0.47), hemoglobin A1C (HbA1C) (ESWMD: −0.57; 95% CI: −0.68 to −0.46), homeostasis model assessment for insulin resistance (HOMA-IR) (ESWMD: −1.04; 95% CI: −1.66 to −0.42, and ESSMD: −0.71; 95% CI: −0.97 to −0.46), insulin (ESWMD: −1.00; 95% CI: −1.70 to −0.30, and ESSMD: −0.63; 95% CI: −0.94 to −0.32), interleukin (IL)-6 (ESSMD: −1.23; 95% CI: −1.61 to −0.85), tumor necrosis factor-α (TNF-α) (ESSMD: −1.04; 95% CI: −1.28 to −0.79), and C-reactive protein (CRP) (ESWMD: −0.62; 95% CI: −0.74 to −0.50, and ESSMD: −1.70; 95% CI: −2.21 to −1.19). The finding of our umbrella showed that the supplementation of BBR could be effective in improving glycemic parameters and inflammatory marker in adults.